The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2016

Filed:

May. 28, 2015
Applicants:

Korea Research Institute of Bioscience and Biotechnology, Daejeon, KR;

Dongguk University Industry-academic Cooperation Foundation, Seoul, KR;

Inventors:

Mi Sun Won, Daejeon, KR;

Kyeong Lee, Seoul, KR;

Bo Kyung Kim, Daejeon, KR;

Hyun Seung Ban, Daejeon, KR;

Seohyun Son, Goyang-si, KR;

Kyung-Sook Chung, Daejeon, KR;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/167 (2006.01); C07D 307/42 (2006.01); C07C 235/24 (2006.01); A61K 45/06 (2006.01); A61K 31/341 (2006.01); C07C 231/12 (2006.01);
U.S. Cl.
CPC ...
C07D 307/42 (2013.01); A61K 31/167 (2013.01); A61K 31/341 (2013.01); A61K 45/06 (2013.01); C07C 231/12 (2013.01); C07C 235/24 (2013.01); C07C 2103/74 (2013.01);
Abstract

The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1α, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, β-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition.


Find Patent Forward Citations

Loading…